Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $1.94
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 12, 26 |
Daily · Wilder smoothing
| HC Wainwright & Co. |
| maintain |
| Buy |
| Buy |
| May 21, 26 | Leerink Partners | maintain | Outperform | Outperform |
| May 21, 24 | Truist Securities | maintain | Buy | Buy |
| Mar 8, 24 | Truist Securities | maintain | Buy | Buy |
| Dec 19, 23 | Stifel | maintain | Buy | Buy |
| Aug 23, 23 | Truist Securities | maintain | Buy | Buy |
| Aug 7, 23 | EF Hutton | maintain | Buy | Buy |
| Jun 6, 23 | EF Hutton | maintain | Buy | Buy |
| May 26, 23 | EF Hutton | maintain | Buy | Buy |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 35.02 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 21.11 | Oscillator | Neutral |
| Williams %R (14) | -88.64 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.11 (Hist -0.01) | Oscillator | Strong Sell |
| Average Directional Index (14) | 22.43 (+DI 20.9 / -DI 35.7) | Trend | Sell |
| EMA 20 | 2.13 | MA | Strong Sell |
| SMA 20 | 2.14 | MA | Strong Sell |
| EMA 50 | 2.27 | MA | Strong Sell |
| SMA 50 | 2.37 | MA | Strong Sell |
| SMA 200 | 2.29 | MA | Strong Sell |
FY2025 · 10-K disclosure
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 6-K | Sep 10, 2026 | 2026-09-10 16:05:06 | View |
| 6-K | Aug 3, 2026 | 2026-08-03 08:00:09 | View |
| 6-K | Aug 3, 2026 | 2026-08-03 07:02:28 | View |
| 4 | Jul 30, 2026 | 2026-07-30 16:13:33 | View |
| 4 | Jul 30, 2026 | 2026-07-30 16:11:29 | View |
| 4 | Jul 30, 2026 | 2026-07-30 16:10:39 | View |
| 4 | Jul 30, 2026 | 2026-07-30 16:09:46 | View |
| 4 | Jul 30, 2026 | 2026-07-30 16:08:48 | View |
| 4 | Jul 30, 2026 | 2026-07-30 16:07:46 | View |
| 4 | Jul 30, 2026 | 2026-07-30 16:06:41 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | CGEN | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 5.2x | -5.5x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -6.9x | EPS est. -0.28 | Discount |
| Price / Book | 2.1x | 2.2x | In line |
| Price / Sales | 2.5x | 16.1x | Discount |
| EV / EBITDA | 5.0x | -8.3x | Discount |
| Return on equity | 42.6% | — | Top tier |
| Gross margin | 86.9% | 85.7% | In line |
| Debt / Equity | 0.03 | 0.03 | Conservative |
| Piotroski / Altman Z | 5/9 | Z -0.24 | Distress |
Discounted cash flow model
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Jul 29, 26 | Levine Zurit | officer: SVP, Business Development | A-Award | 18,000 | — |
| Jul 29, 26 | Levine Zurit | officer: SVP, Business Development | A-Award | 24,000 @ $2.26 | $54.24K |
| Jul 29, 26 | Silberman David | officer: Chief Financial Officer | A-Award | 19,500 | — |
| Jul 29, 26 | Silberman David | officer: Chief Financial Officer | A-Award | 26,000 @ $2.26 | $58.76K |
| Jul 29, 26 | Ophir Eran | director, officer: President and CEO | A-Award | 200,000 @ $2.26 | $452.0K |
| Jul 29, 26 | Cohen-Dayag Anat | director | A-Award | 100,000 @ $2.26 | $226.0K |
| Jul 29, 26 | Perry Eran | director | A-Award | 7,500 | — |
| Jul 29, 26 | Perry Eran | director | A-Award | 10,000 @ $2.26 | $22.60K |
Stock news · updated daily
Compugen (NASDAQ: CGEN) outlined the clinical rationale for its COM701 antibody in platinum-sensitive ovarian cancer and described an expansion of its AI-powered discovery platform into tumor-associated antigen, or TAA, research during a company update event. President and Chief Executive Officer Eran Ophir said COM701, a wholly owned anti-PVRIG antibody, is the company's most advanced internal program.
HOLON, ISRAEL, Oct. 6, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI, today announced that management will participate in a fireside chat at the H.C.
Compugen NASDAQ: CGEN outlined the clinical rationale for its COM701 antibody in platinum-sensitive ovarian cancer and described an expansion of its AI-powered discovery platform into tumor-associated antigen, or TAA, research during a company update event.
Compugen Ltd. (CGEN) Discusses COM701 in Ovarian Cancer, MAIA Trial Preview, and UNIGEN Platform Advancements Transcript
Compugen (NASDAQ: CGEN - Get Free Report) and MiMedx Group (NASDAQ: MDXG - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings. Earnings and Valuation This table compares Compugen and
HOLON, Israel, Sept. 22, 2026 /PRNewswire/ -- Compugen Ltd.
HOLON, Israel, Sept. 8, 2026 /PRNewswire/ -- Compugen Ltd.
Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 3, 2026 | -0.08 | -0.07 | Beat 12.5% | $2.60M |
| May 18, 2026 | -0.07 | -0.08 | Miss -14.3% | $2.18M |
| Mar 2, 2026 | -0.07 | 0.60 | Beat 957.1% | $67.33M |
| Nov 10, 2025 | -0.09 | -0.07 | Beat 22.2% | $1.89M |
| Aug 6, 2025 | -0.07 | -0.08 | Miss -14.3% | $1.26M |
| May 19, 2025 | -0.06 | -0.08 | Miss -33.3% | $2.28M |